Analysis Shows Perioperative Pembrolizumab Efficacy in NSCLC
Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor versus placebo plus chemotherapy in patients with early-stage non‑small cell lung cancer.
Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor versus placebo plus chemotherapy in patients with early‑stage non‑small cell lung cancer (NSCLC).
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT